Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22776394 | 1.00 | MTNR1A (0.48) | MTNR1AMTNR1BGSRCYP1A2GRM8 | |
| SCHEMBL1512848 | 1.00 | MTNR1A (0.48) | MTNR1AMTNR1BGSRCYP1A2GRM8 | |
| SCHEMBL22776508 | 1.00 | MTNR1A (0.48) | MTNR1AMTNR1BGSRCYP1A2GRM8 | |
| SCHEMBL1768663 | 0.92 | MTNR1A (0.43) | MTNR1AMTNR1BGSRCYP1A2GRM8 | |
| SCHEMBL1768665 | 0.92 | MTNR1A (0.43) | MTNR1AMTNR1BGSRCYP1A2GRM8 | |
| SCHEMBL2238055 | 0.88 | OTC (0.57) | GSRCYP1A2KMT2ABLMKDM4E | |
| SCHEMBL3503365 | 0.88 | OTC (0.57) | GSRCYP1A2KMT2ABLMKDM4E | |
| SCHEMBL976174 | 0.88 | OTC (0.57) | GSRCYP1A2KMT2ABLMKDM4E | |
| SCHEMBL180969 | 0.86 | KDM4E (0.56) | GSRCYP1A2KMT2ABLMKDM4E | |
| SCHEMBL236178 | 0.86 | KDM4E (0.56) | GSRCYP1A2KMT2ABLMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | claimed |
| EP-4720086-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2026-04-08 | — | — | EP | claimed |
| EP-4720087-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2026-04-08 | — | — | EP | claimed |
| EP-4658374-A1 | METHODS FOR PREPARING CRYSTALLINE PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2025-12-10 | — | — | EP | claimed |
| EP-4613761-A9 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | claimed |
| EP-4613761-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| WO-2025073222-A1 | GLP-1R/GIPR/GCGR TRIPLE AGONIST ANALOGUE AND USE THEREOF | 深圳湾实验室 | 2025-04-10 | — | — | WO | claimed |
| WO-2024246268-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | ZEALAND PHARMA A/S (DK) | 2024-12-05 | — | — | WO | claimed |
| WO-2024246269-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | ZEALAND PHARMA A/S (DK) | 2024-12-05 | — | — | WO | claimed |
| US-20220251142-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2022-08-11 | — | — | US | claimed |
| EP-3997105-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Protagonist Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| US-20220125885-A1 | GLUCAGON ANALOG AGONISTS AND METHODS OF USING THE SAME | ELI LILLY AND COMPANY | 2022-04-28 | — | — | US | claimed |
| CN-114341161-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 领导医疗有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20220041658-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2022-02-10 | — | — | US | claimed |
| US-20210147889-A1 | METHOD FOR ENHANCING CONTINUOUS PRODUCTION OF A NATURAL COMPOUND DURING EXPONENTIAL GROWTH PHASE AND STATIONARY PHASE OF A MICROORGANISM | Bundesrepublik Deutschland, vertreten durch die Bundesministerin für Wirtschaft und Energie (DE) | 2021-05-20 | — | — | US | claimed |
| CN-112342202-B | Tetrahydromethylpyrimidine carboxylic acid biosynthesis gene and application thereof | 江苏省中国科学院植物研究所 | 2021-04-27 | — | — | CN | claimed |
| CN-112342202-A | Tetrahydromethylpyrimidine carboxylic acid biosynthesis gene and application thereof | 江苏省中国科学院植物研究所 | 2021-02-09 | — | — | CN | claimed |
| WO-2020250855-A1 | CYCLIC PEPTIDE, CELL SCAFFOLD MATERIAL, CELL SEPARATION MATERIAL AND CULTURE MEDIUM | 富士フイルム株式会社 | 2020-12-17 | — | — | WO | claimed |
| EP-3608404-A1 | AN IMPROVED METHOD TO PRODUCE CHEMICAL COMPOUNDS DERIVED FROM OXALOACETATE BY MICROORGANISMS | Technische Universität München (DE) | 2020-02-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251142-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | MTNR1A 811/4885MTNR1B 960/4885GSR 3905/4885 |
| US-20220125885-A1 | GLUCAGON ANALOG AGONISTS AND METHODS OF USING THE SAME | GLP1R, GCG, GCGR | MTNR1A 570/4885MTNR1B 538/4885GSR 564/4885 |
| US-20220041658-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | MTNR1A 811/4885MTNR1B 960/4885GSR 3905/4885 |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, IL36G | MTNR1A 45/4885MTNR1B 94/4885GSR 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.